Risk factors that predict the requirement of aggressive therapy among Chinese patients with Crohn's disease

Journal of Digestive Diseases

Volumn 12, Issue 2, 2011, Pages 99-104

  Yang, Chuan Hua ^a   Ding, Juan ^a   Gao, Yan ^a   Chen, Xiang ^b   Yang, Zhao Bin ^c   Xiao, Shu Dong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI EIGHTH PEOPLE'S HOSPITAL   (China)

^c Zhangzhou Municipal Hospital of Fujian Province   (China)

Author keywords

Chinese patients; Crohn's disease; Risk factors

Indexed keywords

STEROID;

ARTICLE; CHINESE; CONTROLLED STUDY; CROHN DISEASE; DISEASE EXACERBATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CROHN DISEASE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 79952646534     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2011.00484.x     Document Type: Article

References (29)

1. Sonnenberg A. Disability from inflammatory bowel disease among employees in West Germany. Gut 1989; 30: 367-70.
2. Bernstein CN, Kraut A, Blanchard JF etal. The relationship between inflammatory bowel disease and socioeconomic variables. Am J Gastroenterol 2001; 96: 2117-25.
3. Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn's disease - based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26: 146-50.
4. Bernstein CN, Fried M, Krabshuis JH etal. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010; 16: 112-24.
5. Stange EF, Travis SP, Vermeire S etal. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006; 55 (Suppl 1): i1-i15.
6. Present DH, Koelitz BI, Wisch N etal. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double blind study. N Engl J Med 1980; 203: 981-7.
7. Candy S, Wright J, Gerber M etal. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-8.
8. Hanauer SB, Feagan BG, Lichtenstein GR etal. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
9. Sands BE, Blank MA, Patel K, van Deventer SJ; ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004; 2: 912-20.
10. Present DH, Rutgeerts P, Targan S etal. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
11. Hanauer SB. Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol 2003; 17: 131-37.
12. Farrell RJ, Ang Y, Kileen P etal. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000; 47: 514-19.
13. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000; 118: 1018-24.
14. Keane J, Gershon S, Wise RP etal. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
15. Beaugerie L, Seksik P, Nion-Larmurier I etal. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-56.
16. Thompson NP, Wakefield AJ, Pounder RE. Prognosis and prognostic factors in inflammatory bowel disease. Saudi J Gastroenterol 1995; 1: 129-37.
17. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008; 43: 948-54.
18. Beaugerie L, Le Quintrec Y, Paris JC etal. Testing for course patterns in Crohn's disease using clustering analysis. Gastroenterol Clin Biol 1989; 13: 1036-41.
19. Munkholm P, Langholz E, Davidsen M etal. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30: 699-706.
20. Ouyang Q, Hu PJ, Qian JM etal. Consensus on the management of inflammatory bowel disease in China in 2007. J Dig Dis 2008; 9: 52-62.
21. Louis E, Michel V, Hugot JP etal. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 2003; 52: 552-7.
22. Chow DKL, Sung JJY, Wu JCY etal. Upper gastrointestinal tract phenotype of Crohn's Disease is associated with early surgery and further hospitalization. Inflamm Bowel Dis 2009; 15: 551-7.
23. Oriuchi T, Hiwatashi N, Kinouchi Y etal. Clinical course and longterm prognosis of Japanese patients with Crohn's disease: predictive factors, rates of operation, and mortality. J Gastroenterol 2003; 38: 942-53.
24. Romberg-Camps MJ, Dagnelie PC, Kester AD etal. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009; 104: 371-83.
25. Tarrant KM, Barclay ML, Frampton CM etal. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol 2008; 103: 3082-93.
26. Lakatos PL, Czegledi Z, Szamosi T etal. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol 2009; 15: 3504-10.
27. APDW2004 Chinese IBD Working Group. Retrospective analysis of 515 cases of Crohn's disease hospitalization in China: nationwide study from 1990 to 2003. J Gastroenterol Hepatol 2006; 21: 1009-15.
28. Ouyang Q, Pan GZ, Wen ZH etal. Suggested guidelines for the diagnosis and treatment of inflammatory bowel disease. Chin J Dig Dis 2001; 2: 202-8.
29. Ouyang Q, Tandon R, Goh KL etal. Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol 2006; 21: 1772-82.